Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000276
  4. Details
NCT00000276 Clinical Trial

Dopamine Reuptake Inhibitors of Cocaine Abuse - 1

Cocaine-Related Disorders Clinical Trial

Official title:
Dopamine Reuptake Inhibitors of Cocaine Abuse

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00000276
Other study ID # NIDA-09250-1
Secondary ID P50DA009250P50-0
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 1994
Est. completion date August 1999

Study information
Verified date June 2020
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.

Recruitment information / eligibility
Status Terminated
Enrollment 0
Est. completion date August 1999
Est. primary completion date August 1999
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

-

Exclusion Criteria:

-

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Bupropion

Locations
Country Name City State
United States VA Connecticut Healthcare System New Haven Connecticut

Sponsors (3)
Lead Sponsor Collaborator
Yale University National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Side effects
Primary Cocaine effects
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2